Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DG61OC
|
|||
| Drug Name |
MGCD290
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Vulvovaginal Candidiasis [ICD-11: 1F23.10] | Phase 2 | [1] | |
| Company |
Mirati Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fungal Probable histone deacetylase HOS2 (Fung HOS2) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01497223) MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis. U.S. National Institutes of Health. | |||
| REF 2 | Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens. J Clin Microbiol. 2009 Dec;47(12):3797-804. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.